Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Shop Teranode Secures $2.6M Series A Round

NEW YORK, Aug. 6 (GenomeWeb News) - Teranode said last week that it as closed a $2.6M Series A round of financing led by Ignition Partners. Teranode's existing investors - the Washington Research Foundation and Prima Electronics - also participated in the funding round.

 

The Seattle-based firm markets the VLX Design Suite, a biological modeling and experimental design platform. The company's customers include Pfizer, AstraZeneca, FredHutchinsonCancerResearchCenter, and St. Jude's Hospital.

 

Teranode said that its previous funding includes a $1.8 million NIH grant, "undiluted funds" from the NSF and Intel Research, seed funding from the Washington Research foundation, and private investors.

 

The company will use the cash to help expand its development and support teams and invest in marketing and partnerships.

 

This newsbrief originally appeared in BioInform, a GenomeWeb publication.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.